Abstract
The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upperbody obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed “adipokines”). Weight reduction and increased physical activity represent the main approach to tackle the “diabesity” epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.
Keywords: Cathecolamines, stimulatory GTP-binding protein, free fatty acids, Natriuretic peptides, lipolysis, Adiponectin
Current Pharmaceutical Design
Title: Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Volume: 13 Issue: 21
Author(s): Amaia Rodriguez, Victoria Catalan, Javier Gomez-Ambrosi and Gema Fruhbeck
Affiliation:
Keywords: Cathecolamines, stimulatory GTP-binding protein, free fatty acids, Natriuretic peptides, lipolysis, Adiponectin
Abstract: The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upperbody obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed “adipokines”). Weight reduction and increased physical activity represent the main approach to tackle the “diabesity” epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.
Export Options
About this article
Cite this article as:
Amaia Rodriguez , Victoria Catalan , Javier Gomez-Ambrosi and Gema Fruhbeck , Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039599
DOI https://dx.doi.org/10.2174/138161207781039599 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Functional Food with Some Health Benefits, So Called Superfood: A Review
Current Nutrition & Food Science Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Increases in Peripheral Systolic Pressure Levels and Z-score Associate Gradual Aortic Pressure Increase and Functional Arterial Impairment in Children and Adolescents
Current Hypertension Reviews Fenofibrate Increases Heme Oxygenase 1 Expression and Astrocyte Proliferation While Limits Neuronal Injury During Intracerebral Hemorrhage
Current Neurovascular Research Oxidative Stress and Vascular Disease
Current Hypertension Reviews Advanced in Silico Methods for the Development of Anti- Leishmaniasis and Anti-Trypanosomiasis Agents
Current Medicinal Chemistry Lifestyle Modification for Masked Hypertension
Current Hypertension Reviews Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: ‘Lone’ Atrial Fibrillation: No Longer Lone or Even Alone)
Current Pharmaceutical Design Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus
Current Diabetes Reviews Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) A Collaborative Edge-Cloud Internet of Things Based Framework for Securing the Indian Healthcare System
International Journal of Sensors, Wireless Communications and Control The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Obesity in China: What are the Causes?
Current Pharmaceutical Design An Optimal Combination of Chemically Pure Compounds from <i>Salvia miltiorrhiza</i> for Inhibiting Cell Proliferation
Cardiovascular & Hematological Agents in Medicinal Chemistry